Multishield DC Intramammary Suspension

Nchi: Uingereza

Lugha: Kiingereza

Chanzo: HMA (Heads of Medicines Agencies)

Viambatanisho vya kazi:

neomycin 100 mg, procaine 400 mg

Inapatikana kutoka:

Cross Vetpharm Group

ATC kanuni:

QJ51RC

Dawa fomu:

Intramammary suspension

Kundi la matibabu:

lactam antibacterials, penicillins, combinations with other antibacterials

Eneo la matibabu:

Cattle Food

Idhini ya tarehe:

2012-12-21

Tabia za bidhaa

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Multishield DC Intramammary Suspension for Cows.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 4.5g intramammary syringe contains
Active Substances:
Neomycin
70 000 IU
(corresponding to Neomycin Sulphate
100 mg)
Penethamate
77.2 mg
(corresponding to Penethamate Hydriodide
100 mg)
Benzylpenicillin
227.2 mg
(corresponding to Procaine Benzylpenicillin
400 mg)
Excipients:
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Intramammary suspension.
A smooth, off white, oily suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cows (at dry off).
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In cows at drying off:
Treatment of subclinical mastitis caused by bovine mastitis organisms sensitive to the combination of active
substances, penicillin and neomycin, and as part of strategy for the prevention of new infections occurring during the
dry period.
4.3 CONTRAINDICATIONS
Do not use in lactating cows.
Do not use in animals which are known to be hypersensitive to
-lactam antibiotics, cephalosporin antibiotics,
neomycin or other aminoglycoside antibiotics or to iodine.
Do not use in cows with clinical mastitis.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 29/01/2013_
_CRN 7010064_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not
possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the
target bacteria.
Official, national and regional antimicrobial p